First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Market Size and Growth: Analysis of the current market size and projections for the cancer monoclonal antibody market from 2023 to 2032. This includes data on market value and volume, as well as the ...

Association between DNA level aberrations and immune cell infiltration in breast cancer. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not include a full ...

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

The global monoclonal antibodies market is poised for robust expansion, projected to surge from USD 208.32 billion in 2022 to USD 647.01 billion by 2032, reflecting a CAGR of 12% over the forecast ...

Next, anti-CTLA-4 monoclonal antibodies were newly established and characterized for their binding properties and functional blockade of the CTLA-4 axis. A caninized (canine-ized) anti-CTLA-4 antibody ...

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer ...

the reported MIA methods commonly require multiple antibodies since each antibody can recognize only one antigen. Herein, a novel bispecific monoclonal antibody (BsMcAb) that could bind methyl ...